Hepatitis B Virus Kinetics Under Antiviral Therapy Sheds Light on Differences in Hepatitis B e Antigen Positive and Negative Infections

作者: Ruy M. Ribeiro , Georgios Germanidis , Kimberly A. Powers , Bertrand Pellegrin , Paul Nikolaidis

DOI: 10.1086/656528

关键词:

摘要: Approximately 2 billion people have been infected with hepatitis B virus (HBV) in their lifetime [1, 2]. Since only a small percentage of adults develops chronic B, global prevalence this disease is estimated at 350 million [1]. End-stage HBV infection can lead to cirrhosis and hepatocellular carcinoma (HCC), up 1.2 die every year from the consequences [1]. Chronic (CHB) usually characterized by detectable DNA serum, as well presence surface antigen (HBsAg). Hepatitis e (HBeAg) also be present. However, large proportion individuals are HBeAg-negative [3], because they variants that unable produce high amounts excreted protein bears HBe epitope. These mutants rather uncommon North America Northern Europe, but vast majority patients CHB Southern Europe Africa express little or no HBeAg, seems increasing worldwide [3–5]. Infection associated lower serum viral levels [6–8], higher intra-hepatic necroinflammatory lesions more severe progression disease, frequent development and/or HCC [9, 10], than HBeAg-positive strains [6, 11]. Taken together these observations may indicate stronger immune response against infection. Consistent this, even though function not clear, it has suggested serves down modulate [12, 13]. In addition, represent difficult treat patient pool, due off-treatment sustained responses [7, 14, 15]. Modeling different infections treatment given insight into aspects evolution, pathogenesis mechanisms antiviral drug action [16–20]. Such analyses showed short half-life plasma rapid production. We others calculated daily production excess 1011 virions cell lifespan very variable days [21, 22]. A few studies analyzed effect therapy on kinetics [23, 24]. The results suggest clearance faster setting infection. Here we analyze dynamics under variety treatments conduct an exhaustive meta-analysis published concerning dynamics. Our goal was understand respective roles compare them

参考文章(44)
F. Bonino, F. Rosina, M. Rizzetto, R. Rizzi, E. Chiaberge, R. Tardanico, F. Callea, G. Verme, Chronic hepatitis in HBsAg carriers with serum HBV-DNA and Anti-HBe Gastroenterology. ,vol. 90, pp. 1268- 1273 ,(1986) , 10.1016/0016-5085(86)90395-1
John M. Murray, Robert H. Purcell, Stefan F. Wieland, The half-life of hepatitis B virions Hepatology. ,vol. 44, pp. 1117- 1121 ,(2006) , 10.1002/HEP.21364
Manuel Tsiang, James F. Rooney, John J. Toole, Craig S. Gibbs, Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy Hepatology. ,vol. 29, pp. 1863- 1869 ,(1999) , 10.1002/HEP.510290626
Sharon R Lewin, Ruy M Ribeiro, Tomos Walters, George K Lau, Scott Bowden, Stephen Locarnini, Alan S Perelson, Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed Hepatology. ,vol. 34, pp. 1012- 1020 ,(2001) , 10.1053/JHEP.2001.28509
C. C. Wang, S. Holte, M.-L. Huang, S. L. Sacks, R. Engelberg, J. Ferrenberg, M. Shuhart, L. Corey, Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg vs 100 mg of lamivudine daily. Journal of Viral Hepatitis. ,vol. 11, pp. 443- 447 ,(2004) , 10.1111/J.1365-2893.2004.00523.X
David Milich, T Jake Liang, Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection Hepatology. ,vol. 38, pp. 1075- 1086 ,(2003) , 10.1053/JHEP.2003.50453
Lars Frelin, Therese Wahlström, Amy E. Tucker, Joyce Jones, Janice Hughes, Byung O. Lee, Jean-Noel Billaud, Cory Peters, David Whitacre, Darrell Peterson, David R. Milich, A Mechanism To Explain the Selection of the Hepatitis e Antigen-Negative Mutant during Chronic Hepatitis B Virus Infection Journal of Virology. ,vol. 83, pp. 1379- 1392 ,(2009) , 10.1128/JVI.01902-08
Alan S. Perelson, Eva Herrmann, Florence Micol, Stefan Zeuzem, New kinetic models for the hepatitis C virus Hepatology. ,vol. 42, pp. 749- 754 ,(2005) , 10.1002/HEP.20882
Ruy M. Ribeiro, Arthur Lo, Alan S. Perelson, Dynamics of hepatitis B virus infection. Microbes and Infection. ,vol. 4, pp. 829- 835 ,(2002) , 10.1016/S1286-4579(02)01603-9
Vassiliki-Anastasia Sypsa, Konstantinos Mimidis, Nicholas C. Tassopoulos, Dimitrios Chrysagis, Themistoklis Vassiliadis, Antonios Moulakakis, Maria Raptopoulou, Caterina Haida, Angelos Hatzakis, A viral kinetic study using pegylated interferon alfa‐2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative Hepatology. ,vol. 42, pp. 77- 85 ,(2005) , 10.1002/HEP.20738